LC-MS Glycan Characterization Strategies Using Middle-up and RapiFluor-MS Released N-Glycans
Available on demand
Therapeutic antibodies produced in mammalian expression systems typically exhibit two N-glycans in the CH2 domain of the Fc region. Fc glycosylation can significantly modify Fc effector functions such as Fc receptor binding and antibody dependent cellular cytotoxicity. It is possible for a glycoform present in relatively low abundance to have a dramatic influence on product efficacy.
In addition to Fc glycosylation, some recombinant mAbs exhibit Fab glycosylation. Given the size and proximity of such oligosaccharides to the antigen binding site, glycosylation would be expected to profoundly influence antigen binding. Consequently, with respect to product development and characterization strategies which permit separate evaluation of Fc- and Fab-glycosylation are valuable for connecting structure to function.
In this webinar, Dr David Firth PhD, Senior Scientist at Covance, will discuss:
- Product development and characterization strategies for connecting glycan structure to function
- Integrated analytical workflows from sample preparation through informatics that help to streamline and simplify this type of work
Waters